201
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

A phase II clinical trial of lenalidomide intensification in patients with serologic/asymptomatic progression of multiple myeloma while on lenalidomide maintenance: a tri-state transplant consortium study

, , , , , , , ORCID Icon, & show all
Pages 488-490 | Received 31 Aug 2019, Accepted 20 Sep 2019, Published online: 19 Jan 2020
 

Disclosure statement

Study was supported by an unrestricted research grant provided by Celgene corporation to the TriState Transplant Consortium. Dr Giralt has research support from CELGENE, Amgen, Takeda, Miltenyi, Novartis, Sanofi and has served as consultant to those companies. Other authors have provided conflict of interest disclosures.

Additional information

Funding

The Tri-State Transplant Consortium and this project were funded in part through a research grant obtained from CELGENE Corporation.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.